By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Excess Medtech Cash Leading to More Acquisition, Less IPO
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Excess Medtech Cash Leading to More Acquisition, Less IPO
Business

Excess Medtech Cash Leading to More Acquisition, Less IPO

PatrickDriscoll
PatrickDriscoll
Share
3 Min Read
SHARE

Based on a recent JP Morgan analysis of year end 2011 SEC filings, the top ten medtech companies have roughly $57 billion in cash.  This translates to principally one thing: acquisition.  Such is the case with Medtronic’s $755 million acquisition of China Kanghui Holdings and Boston Scientific’s $265 million buy of Rhythmia Medical, two acquisitions that highlight key areas of focus for medtech companies.

Based on a recent JP Morgan analysis of year end 2011 SEC filings, the top ten medtech companies have roughly $57 billion in cash.  This translates to principally one thing: acquisition.  Such is the case with Medtronic’s $755 million acquisition of China Kanghui Holdings and Boston Scientific’s $265 million buy of Rhythmia Medical, two acquisitions that highlight key areas of focus for medtech companies.

The first is medtech companies’ interest in strengthening their positions in emerging markets.  Medtronic’s acquisition of China Kanghui will give the company valuable access to orthopedic markets in China due to China Kanghui’s product and distribution focus. Medtronic has proven time and again that it is uniquely successful at expanding its presence geographically in growth markets and the Kanghui acquisition should serve as a model for medtech companies with global interests.

The second are of focus is gaining breadth and depth serving areas of existing clinical focus. Like Medtronic, Boston Scientific is also proficient at identifying acquisitions to serve this end.  The company’s $265 million acquisition of Rhythmia Medical will bolster BSCI’s position in electrophysiology and arrhythmia management, two areas of profitable opportunity that complement the company’s existing portfolio in cardiology markets. Similarly is J&J’s acquisition of Synthes, Royal DSM’s acquisition of Kensey Nash, Covidien’s acquisition of superDimension Ltd, Maya Medical, and CNS Therapeutics, and others.

More Read

Physicians to Lead ACOs, AMA Says
How the Uber-ization of Healthcare is Going to Put the Industry in Gear
Is Cost-Effective Medicine on Life Support?
The Stunning Shift Toward Employed Physicians
New Guide Explains Hospitalist Role

A predictable cycle is apparent here. The institutional investment that led to a proliferation of medtech companies was ultimately pinched by the credit crunch and accompanying deep recession begun in 2008.  Companies founded immediately before or during this time frame, if even able to survive development stage cash flow challenges, have inevitably had to face a daunting 7-10 year regulatory approval process that turned them into cash-poor technology innovators.  Meanwhile, large cap medtech companies with long-term views recognized that several years of very modest market growth coupled with conservative management of their assets has led to cash reserves that now beg to be spent filling out these companies’ product and technology portfolios.

All of this leads one to expect that the uncertain market for IPOs in medtech is clearly undercut by the potential for private harvesting. Companies with excess cash and specific technology or emerging market interest will displace the opportunity for public offerings.

 

 

    

TAGGED:medtech
Share This Article
Facebook Copy Link Print
Share
By PatrickDriscoll
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Epidemiological Health Benefits
Personal and Epidemiological Health Benefits of Blood Pressure Management
Health
October 13, 2025
Traumatic Brain Injuries
Understanding Traumatic Brain Injuries: What Families Need to Know
Policy & Law
October 10, 2025
Remote Monitoring touchpoints
Remote Monitoring Touchpoints Patients Will Actually Follow
Technology
October 9, 2025
dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025

You Might also Like

Sutures, staples, clips in wound closure

June 6, 2011

Peter Diamond for Chief Economic Adviser

June 8, 2011
Market Segmentation
BusinessFinanceMedical DevicesTechnology

Defining the Point of Care Market

February 12, 2014

Changing Behavior to Conquer Obesity

September 23, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?